Corcept Therapeutics Inc. (CORT), a commercial-stage company developing medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders, has a couple of catalysts to watch this year.
The lead drug candidate is Relacorilant, a non-steroidal, selective glucocorticoid receptor modulator that is being evaluated in a variety of serious disorders, including Cushing's syndrome, ovarian cancer and adrenal cancer.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.